# Odyssey Therapeutics, Inc. — Form D

Odyssey Therapeutics, Inc. of BOSTON, MA, a company, filed a Form D exempt-offering notice with the SEC on 2025-12-04. The offering totals $214.0M, of which $214.0M was reported sold. Industry: Biotechnology.

## Offering

- Filed: 2025-12-04
- Form: D
- Accession: 0001104659-25-118426
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $214.0M
- Amount sold: $214.0M
- Investors: 55
- Date of first sale: 2025-06-16
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-565797

## Issuer

- Name: Odyssey Therapeutics, Inc.
- CIK: 0001882782
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2021
- Address: 51 SLEEPER STREET, BOSTON, MA, 02210
- Phone: 617-865-9628

## Officers, directors & promoters (25)

| Name | Role | Location |
| --- | --- | --- |
| Shelley F Chu | Director | Boston, MA |
| Paulina D Hill | Director | Boston, MA |
| Nan D Li | Director | Boston, MA |
| Carolyn F Ng | Director | Boston, CA |
| Ksenija F Pavletic | Director | Boston, MA |
| lan F Smith | Director | Boston, MA |
| Nia F Tatsis | Director | Boston, MA |
| Timothy D Walbert | Director | Boston, MA |
| Jason F Haas | Executive Officer | Boston, MA |
| Timothy M Walbert | Director | Boston, MA |
| Charles M Baum | Director | Boston, MA |
| Jeffrey M Leiden | Director | Boston, MA |
| Ian M Smith | Director | Boston, MA |
| Lorence M Kim | Director | Boston, MA |
| Jeffrey Charles Leiden | Director | Boston, MA |
| M. Charles Baum | Director | Boston, MA |
| Lorence Charles Kim | Director | Boston, MA |
| Valerie D Odegard | Director | Cambridge, MA |
| Jill D Carroll | Director | Cambridge, MA |
| Carl D Gordon | Director | Cambridge, MA |
| Jeffrey D Leiden | Director | Cambridge, MA |
| Charles D Baum | Director | Cambridge, MA |
| Gary D Glick | Director | Cambridge, MA |
| Gary D Glick | Executive Officer | Cambridge, MA |
| Chuck D Baum | Director | MEDFIELD, MA |

## Other filings by this issuer (4)

| Filed | Form | Offering | Sold |
| --- | --- | --- | --- |
| [2024-08-14](https://search.stillhousedata.com/formd/0001882782-24-000001) | D/A | $121.1M | $117.2M |
| [2023-12-15](https://search.stillhousedata.com/formd/0001882782-23-000001) | D | $106.0M | $97.1M |
| [2022-10-27](https://search.stillhousedata.com/formd/0001882782-22-000002) | D | $174.9M | $168.0M |
| [2021-10-14](https://search.stillhousedata.com/formd/0001882782-21-000001) | D | — | $91.6M |

## More

- [CIK 1882782 on SEC EDGAR (source of record)](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1882782&type=&dateb=&owner=include&count=40)
- [This page as markdown (for LLM agents)](https://search.stillhousedata.com/formd/0001104659-25-118426.md)
- [Search all SEC filings, advisers and people on Adviser Search](https://search.stillhousedata.com/)

---

Source: public SEC filing data via Adviser Search (https://search.stillhousedata.com).
Agents: this data is also queryable via MCP tools and read-only SQL — see https://search.stillhousedata.com/llms.txt.